Nanoparticles could have giant impact on drug development

05/7/2013 | Reuters

Bind Therapeutics has agreed to three deals potentially worth a total of $1 billion to help drugmakers develop nanomedicine. Drugs incorporating nanoparticles of polymers, gold and graphene are in various stages of development, including 117 oncology drugs, according to Thomson Reuters Pharma. Nanoparticles may allow targeted treatment of tumors with fewer side effects than conventional therapies and may also be useful in drugs for inflammatory disorders, pain, and heart and brain diseases, as well as diagnostics.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX